<p>Cognition Therapeutics, Inc. (NASDAQ: CGTX - 获取免费报告) 在六月份的短期利空方面受到了大幅减少。截至 6 月 15 日，总共有 180,700 股的空头头寸，较 5 月 31 日的 210,600 股减少了 14.2%。公司约有 0.5% 的股份被卖空。基于平均交易量为 144,300 股，目前的空头头寸比率为 1.3 天。</p>
<p>获取 <strong>Cognition Therapeutics</strong> 警报：</p>
<h2>Cognition Therapeutics 价格表现</h2>
<p>NASDAQ: CGTX 股票在周一交易中上涨了$0.01，达到$1.67。该股交易量为 79,644 股，相比平均交易量 177,680 股有所下降。该股的 50 天移动平均价为$2.02，200 天移动平均价为$2.01。Cognition Therapeutics 的一年最低价为$0.90，最高价为$2.95。该公司的市值为 6690 万美元，市盈率为-1.82，贝塔系数为 1.48。</p>
<p>Cognition Therapeutics (NASDAQ: CGTX - 获取免费报告) 最近发布了其季度财报，日期为 5 月 7 日。公司报告该季度每股亏损 ($0.27)，低于市场预期的 ($0.23)。卖方分析师预测，Cognition Therapeutics 今年将发布-0.97 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>一些股票研究分析师最近对该公司发表了评论。B. Riley 在 3 月 28 日星期四重申了对 Cognition Therapeutics 股票的 “买入” 评级，并设定了$5.00 的目标价。Oppenheimer 在 3 月 27 日星期三重申了对 Cognition Therapeutics 股票的 “表现优异” 评级，并设定了$9.00 的价格目标。HC Wainwright 在 5 月 29 日星期三开始对 Cognition Therapeutics 股票进行覆盖。他们给予该股 “买入” 评级，并设定了$10.00 的目标价。最后，Chardan Capital 在 6 月 6 日星期四对 Cognition Therapeutics 股票进行了覆盖。他们给予该公司 “买入” 评级，并设定了$11.00 的价格目标。根据 MarketBeat 的数据，五位研究分析师对该股票给予买入评级。目前，市场普遍评级为 “买入”，平均目标价为$8.20。</p>
<p><strong>查看我们关于 CGTX 的最新股票报告</strong></p>
<h2>对 Cognition Therapeutics 的对冲基金看法</h2>
<p>大型投资者最近增加或减少了他们在该公司的持股。AWM Investment Company Inc.在第一季度购入了 Cognition Therapeutics 股票，价值约 118.3 万美元。Hohimer Wealth Management LLC 在第一季度购入了 Cognition Therapeutics 的新头寸，价值 41 万美元。CM Management LLC 在第一季度购入了 Cognition Therapeutics 的新头寸，价值 31.8 万美元。Twin Focus Capital Partners LLC 在第四季度购入了 Cognition Therapeutics 股票，价值 17.3 万美元。最后，Texas Capital Bank Wealth Management Services Inc.在第四季度购入了 Cognition Therapeutics 股票，价值约 10.2 万美元。机构投资者持有该公司 43.35% 的股份。</p>
<h2>关于 Cognition Therapeutics（获取免费报告）</h2>
<p>Cognition Therapeutics, Inc.是一家临床阶段的生物制药公司，致力于发现和开发针对年龄相关退行性疾病、中枢神经系统和视网膜疾病的小分子治疗药物。其主要产品候选药物是 CT1812，一种口服分子调节剂，设计用于穿透血脑屏障并选择性结合到 S2R 复合物，目前正在进行治疗阿尔茨海默病的 2 期临床试验，以及治疗干性老年性黄斑变性和α-突触核病等疾病。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票比 Cognition Therapeutics 更好</li>
<li>股票交易：RSI 及其用途</li>
<li>这三家顶级银行在通过联邦压力测试后提高了股息</li>
<li>交易停牌解释</li>
<li>乘坐 Lyft 股票在下半年获得两位数增长</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>艾礼莉股票上涨：GLP-1 Zepbound 瞄准睡眠呼吸暂停市场</li>
</ul>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
<p>→ 乔·拜登刚刚透露了他的接班人？（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg0"/></p>
<h2>您现在是否应该投资$1,000 在 Cognition Therapeutics？</h2>
<p>在考虑投资 Cognition Therapeutics 之前，您可能会想听听这个。</p>
<p>MarketBeat 追踪华尔街顶级评级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Cognition Therapeutics 并不在名单上。</p>
<p>尽管 Cognition Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CGTX

<p>Cognition Therapeutics, Inc.在六月份经历了空头头寸的显著下降，与上个月相比下降了 14.2%。该公司的股票目前被空头卖出率为 0.5%，空头头寸比率为 1.3 天。该股的交易量和价格也一直在波动。分析师们给予该股票 “买入” 的共识评级，并设定了 8.20 美元的价格目标。机构投资者持有该公司股票的比例为 43.35%。Cognition Therapeutics 是一家专注于开发针对年龄相关性退行性疾病和中枢神经系统疾病的治疗药物的临床阶段生物制药公司</p>

<p>Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 180,700 shares, a drop of 14.2% from the May 31st total of 210,600 shares. Approximately 0.5% of the company's shares are sold short. Based on an average trading volume of 144,300 shares, the short-interest ratio is presently 1.3 days.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc. (NASDAQ: CGTX - 获取免费报告) 在六月份的短期利空方面受到了大幅减少。截至 6 月 15 日，总共有 180,700 股的空头头寸，较 5 月 31 日的 210,600 股减少了 14.2%。公司约有 0.5% 的股份被卖空。基于平均交易量为 144,300 股，目前的空头头寸比率为 1.3 天。</p>
</div><p>Get <strong>Cognition Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cognition Therapeutics</strong> 警报：</p>
</div><h2>Cognition Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 价格表现</h2>
</div><p>Shares of NASDAQ:CGTX traded up $0.01 during trading on Monday, reaching $1.67. 79,644 shares of the stock were exchanged, compared to its average volume of 177,680. The stock has a fifty day moving average of $2.02 and a two-hundred day moving average of $2.01. Cognition Therapeutics has a 1-year low of $0.90 and a 1-year high of $2.95. The firm has a market cap of $66.90 million, a price-to-earnings ratio of -1.82 and a beta of 1.48.</p>
<div class="lb-trans"><p>NASDAQ: CGTX 股票在周一交易中上涨了$0.01，达到$1.67。该股交易量为 79,644 股，相比平均交易量 177,680 股有所下降。该股的 50 天移动平均价为$2.02，200 天移动平均价为$2.01。Cognition Therapeutics 的一年最低价为$0.90，最高价为$2.95。该公司的市值为 6690 万美元，市盈率为-1.82，贝塔系数为 1.48。</p>
</div><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Sell-side analysts forecast that Cognition Therapeutics will post -0.97 EPS for the current year.</p>
<div class="lb-trans"><p>Cognition Therapeutics (NASDAQ: CGTX - 获取免费报告) 最近发布了其季度财报，日期为 5 月 7 日。公司报告该季度每股亏损 ($0.27)，低于市场预期的 ($0.23)。卖方分析师预测，Cognition Therapeutics 今年将发布-0.97 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities research analysts recently commented on the company. B. Riley restated a &#34;buy&#34; rating and set a $5.00 target price on shares of Cognition Therapeutics in a research report on Thursday, March 28th. Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $9.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday, March 27th. HC Wainwright initiated coverage on shares of Cognition Therapeutics in a research report on Wednesday, May 29th. They set a &#34;buy&#34; rating and a $10.00 target price on the stock. Finally, Chardan Capital assumed coverage on shares of Cognition Therapeutics in a report on Thursday, June 6th. They issued a &#34;buy&#34; rating and a $11.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $8.20.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该公司发表了评论。B. Riley 在 3 月 28 日星期四重申了对 Cognition Therapeutics 股票的 “买入” 评级，并设定了$5.00 的目标价。Oppenheimer 在 3 月 27 日星期三重申了对 Cognition Therapeutics 股票的 “表现优异” 评级，并设定了$9.00 的价格目标。HC Wainwright 在 5 月 29 日星期三开始对 Cognition Therapeutics 股票进行覆盖。他们给予该股 “买入” 评级，并设定了$10.00 的目标价。最后，Chardan Capital 在 6 月 6 日星期四对 Cognition Therapeutics 股票进行了覆盖。他们给予该公司 “买入” 评级，并设定了$11.00 的价格目标。根据 MarketBeat 的数据，五位研究分析师对该股票给予买入评级。目前，市场普遍评级为 “买入”，平均目标价为$8.20。</p>
</div><p><strong>Check Out Our Latest Stock Report on CGTX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CGTX 的最新股票报告</strong></p>
</div><h2>Hedge Funds Weigh In On Cognition Therapeutics</h2>
<div class="lb-trans"><h2>对 Cognition Therapeutics 的对冲基金看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. purchased a new stake in shares of Cognition Therapeutics in the first quarter worth approximately $1,183,000. Hohimer Wealth Management LLC bought a new position in Cognition Therapeutics during the 1st quarter valued at $410,000. CM Management LLC purchased a new position in Cognition Therapeutics during the 1st quarter worth $318,000. Twin Focus Capital Partners LLC bought a new stake in shares of Cognition Therapeutics in the 4th quarter worth $173,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $102,000. Institutional investors own 43.35% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了他们在该公司的持股。AWM Investment Company Inc.在第一季度购入了 Cognition Therapeutics 股票，价值约 118.3 万美元。Hohimer Wealth Management LLC 在第一季度购入了 Cognition Therapeutics 的新头寸，价值 41 万美元。CM Management LLC 在第一季度购入了 Cognition Therapeutics 的新头寸，价值 31.8 万美元。Twin Focus Capital Partners LLC 在第四季度购入了 Cognition Therapeutics 股票，价值 17.3 万美元。最后，Texas Capital Bank Wealth Management Services Inc.在第四季度购入了 Cognition Therapeutics 股票，价值约 10.2 万美元。机构投资者持有该公司 43.35% 的股份。</p>
</div><h2>About Cognition Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Cognition Therapeutics（获取免费报告）</h2>
</div><p>Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc.是一家临床阶段的生物制药公司，致力于发现和开发针对年龄相关退行性疾病、中枢神经系统和视网膜疾病的小分子治疗药物。其主要产品候选药物是 CT1812，一种口服分子调节剂，设计用于穿透血脑屏障并选择性结合到 S2R 复合物，目前正在进行治疗阿尔茨海默病的 2 期临床试验，以及治疗干性老年性黄斑变性和α-突触核病等疾病。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Cognition Therapeutics</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>These Top 3 Banks Raise Dividends After Passing Fed Stress Test</li>
<li>Trading Halts Explained</li>
<li>Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票比 Cognition Therapeutics 更好</li>
<li>股票交易：RSI 及其用途</li>
<li>这三家顶级银行在通过联邦压力测试后提高了股息</li>
<li>交易停牌解释</li>
<li>乘坐 Lyft 股票在下半年获得两位数增长</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>艾礼莉股票上涨：GLP-1 Zepbound 瞄准睡眠呼吸暂停市场</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><p>→ Did Joe Biden just reveal his replacement? (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 乔·拜登刚刚透露了他的接班人？（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8584&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cognition Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 在 Cognition Therapeutics？</h2>
</div><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Cognition Therapeutics 之前，您可能会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶级评级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Cognition Therapeutics 并不在名单上。</p>
</div><p>While Cognition Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Cognition Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cognition Therapeutics 公司（纳斯达克股票代码：CGTX）空头头寸更新